Analysts See $-0.30 EPS for Clementia Pharmaceuticals Inc. (CMTA); Ticc Capital Has 1.1 Sentiment

January 14, 2018 - By Michael Collier

Analysts expect Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) to report $-0.30 EPS on February, 12.After having $-1.83 EPS previously, Clementia Pharmaceuticals Inc.’s analysts see -83.61% EPS growth. The stock increased 1.21% or $0.2 during the last trading session, reaching $16.73. About 19,449 shares traded. Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

TICC Capital Corp. is a business development company, operates as a closed-end, non-diversified management investment company. The company has market cap of $291.37 million. The firm invests in both public and private companies. It has a 4.85 P/E ratio. It invests in secured and unsecured senior debt, subordinated debt, junior subordinated debt, preferred stock, and common stock.

The stock increased 0.53% or $0.03 during the last trading session, reaching $5.66. About 244,976 shares traded. TICC Capital Corp. (TICC) has risen 38.21% since January 14, 2017 and is uptrending. It has outperformed by 21.51% the S&P500.

Selz Capital Llc holds 1% of its portfolio in TICC Capital Corp. for 727,000 shares. Lucus Advisors Llc owns 33,900 shares or 0.33% of their US portfolio. Moreover, Nine Chapters Capital Management Llc has 0.23% invested in the company for 15,000 shares. The Ontario – Canada-based Hillsdale Investment Management Inc. has invested 0.22% in the stock. Gsa Capital Partners Llp, a United Kingdom-based fund reported 210,900 shares.

Since January 1, 0001, it had 2 insider buys, and 0 selling transactions for $468,392 activity.

Analysts await TICC Capital Corp. (NASDAQ:TICC) to report earnings on March, 1. They expect $0.13 earnings per share, down 7.14% or $0.01 from last year’s $0.14 per share. TICC’s profit will be $6.69 million for 10.88 P/E if the $0.13 EPS becomes a reality. After $0.13 actual earnings per share reported by TICC Capital Corp. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. The company has market cap of $530.64 million. The Company’s lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models. It currently has negative earnings. The firm is developing palovarotene for the treatment of fibrodysplasia ossificans progressiva and multiple osteochondroma, as well as has one Phase III and Phase II/III trials for two separate indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News